MA44209A - Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate - Google Patents

Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate

Info

Publication number: MA44209A
Authority: MA; Morocco
Prior art keywords: phosphorodiamidate oligomer; phosphorodiamidate; oligomer; pure; preparing
Prior art date: 2015-08-05

Application number

MA044209A

Other languages

English (en)

Other versions

MA44209B1 (fr

Inventor

Hyeong Wook Choi

Atsushi Endo

Francis Fang

Mingde Shan

Robert T Yu

Original Assignee

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-05

Filing date

2016-08-05

Publication date

2021-04-28

2016-08-05 Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd

2021-04-28 Publication of MA44209A publication Critical patent/MA44209A/fr

2022-03-31 Publication of MA44209B1 publication Critical patent/MA44209B1/fr

Links

ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 title 3
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000008569 process Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA44209A 2015-08-05 2016-08-05 Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate MA44209B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562201510P	2015-08-05	2015-08-05
PCT/US2016/045876 WO2017024264A2 (fr)	2015-08-05	2016-08-05	Réactifs chiraux pour la préparation d'oligomères homogènes

Publications (2)

Publication Number	Publication Date
MA44209A true MA44209A (fr)	2021-04-28
MA44209B1 MA44209B1 (fr)	2022-03-31

Family

ID=56943909

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA44209A MA44209B1 (fr)	2015-08-05	2016-08-05	Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate

Country Status (31)

Country	Link
US (4)	US10457698B2 (fr)
EP (2)	EP3331891B1 (fr)
JP (4)	JP6978406B2 (fr)
KR (2)	KR20250005537A (fr)
CN (3)	CN108350005B (fr)
AU (3)	AU2016302009B2 (fr)
CA (1)	CA3296518A1 (fr)
CL (1)	CL2018000322A1 (fr)
CO (1)	CO2018001615A2 (fr)
CY (1)	CY1125552T1 (fr)
DK (1)	DK3331891T3 (fr)
ES (2)	ES2907629T3 (fr)
HR (1)	HRP20220129T1 (fr)
HU (2)	HUE057593T2 (fr)
IL (3)	IL293066A (fr)
LT (1)	LT3331891T (fr)
MA (1)	MA44209B1 (fr)
MD (1)	MD3331891T2 (fr)
MX (2)	MX389022B (fr)
MY (1)	MY196627A (fr)
NZ (2)	NZ778825A (fr)
PE (2)	PE20231843A1 (fr)
PH (1)	PH12018500265A1 (fr)
PL (1)	PL3331891T3 (fr)
PT (1)	PT3331891T (fr)
RS (1)	RS62930B1 (fr)
SI (1)	SI3331891T1 (fr)
SM (1)	SMT202200089T1 (fr)
UA (1)	UA123995C2 (fr)
WO (1)	WO2017024264A2 (fr)
ZA (3)	ZA201801518B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS62930B1 (sr) *	2015-08-05	2022-03-31	Eisai R&D Man Co Ltd	Postupak za pripremu suštinski dijastereomerno čistog fosforodiamidatnog oligomera, fosforodiamidatni oligomer proizveden takvim postupkom i farmaceutska kompozicija koja sadrži fosforodiamidatni oligomer
AU2017330276B2 (en) *	2016-09-20	2022-01-20	The Regents Of The University Of Colorado, A Body Corporate	Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
IL294271A (en)	2019-12-26	2022-08-01	Nippon Shinyaku Co Ltd	Antisense nucleic acid that induces skipping of exon 50
PE20230237A1 (es)	2020-02-28	2023-02-07	Nippon Shinyaku Co Ltd	Acidos nucleicos antisentido que inducen la omision del exon 51
US20220195437A1 (en)	2020-12-11	2022-06-23	Eisai R&D Management Co., Ltd.	Tau-targeting oligonucleotide gapmers
JP2023553360A (ja)	2020-12-11	2023-12-21	エーザイ・アール・アンド・ディー・マネジメント株式会社	ポリ－モルホリノオリゴヌクレオチドギャップマー
PE20252304A1 (es)	2021-04-28	2025-09-22	Eisai Randd Man Co Ltd	Oligonucleotidos antisentido y su uso para el tratamiento de trastornos neurodegenerativos
EP4551580A2 (fr) *	2022-07-07	2025-05-14	Eisai R&D Management Co., Ltd.	Monomères cristallins pour la préparation d'oligonucléotides antisens et leurs procédés de préparation et d'utilisation
KR20250099172A (ko)	2022-10-27	2025-07-01	에자이 알앤드디 매니지먼트 가부시키가이샤	펩티드-안티센스 올리고뉴클레오티드 및 신경퇴행성 장애의 치료를 위한 이들의 용도
EP4658280A2 (fr) *	2023-02-01	2025-12-10	Alnylam Pharmaceuticals, Inc.	Cycle à six chaînons contenant des oligomères

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US6117993A (en) *	1995-05-23	2000-09-12	Hybridon, Inc.	Synthons for oligonucleotide synthesis
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5874554A (en)	1996-12-13	1999-02-23	Incyte Pharmaceuticals, Inc.	Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices
US6306599B1 (en) *	1999-07-16	2001-10-23	Agilent Technologies Inc.	Biopolymer arrays and their fabrication
EP1176151B1 (fr)	2000-07-28	2014-08-20	Agilent Technologies, Inc.	Synthèse des polynucléotides utilisant la chimie combinée d'oxidation et de protection
AR036122A1 (es)	2001-07-03	2004-08-11	Avecia Biotechnology Inc	Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
US8076476B2 (en)	2007-11-15	2011-12-13	Avi Biopharma, Inc.	Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
MX2010004955A (es) *	2007-11-15	2010-06-30	Avi Biopharma Inc	Metodo de sintesis de oligomeros de morfolina.
WO2011018798A2 (fr)	2009-08-14	2011-02-17	Indian Association For The Cultivation Of Science	Agent antisens fondé sur des morpholinos
KR101981705B1 (ko) *	2010-05-28	2019-05-24	사렙타 쎄러퓨틱스, 인코퍼레이티드	변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
CN103154009B (zh)	2010-09-30	2015-06-10	日本新药株式会社	吗啉基核酸衍生物
US9161948B2 (en) *	2011-05-05	2015-10-20	Sarepta Therapeutics, Inc.	Peptide oligonucleotide conjugates
AU2011367230B2 (en) *	2011-05-05	2017-08-10	Sarepta Therapeutics, Inc.	Peptide oligonucleotide conjugates
ES2661705T3 (es)	2011-10-07	2018-04-03	Gilead Sciences, Inc.	Métodos para la preparación de análogos de nucleótidos antivirales
KR20140097398A (ko)	2011-11-18	2014-08-06	사렙타 쎄러퓨틱스, 인코퍼레이티드	기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
WO2013082548A1 (fr)	2011-11-30	2013-06-06	Sarepta Therapeutics, Inc.	Oligonucléotides pour le traitement de maladies à répétition nucléotidique étendue
CN102702265A (zh) *	2012-05-14	2012-10-03	天津特安化学科技有限公司	一种固相合成磷酰二胺吗啉代寡核苷酸及方法
DE102015214943A1 (de)	2015-08-05	2017-02-09	Siemens Aktiengesellschaft	Verfahren und Anlage für eine chemische Synthese
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MY188405A (en)	2015-08-05	2021-12-08	Janssen Biotech Inc	Anti-cd154 antibodies and methods of using them
RS62930B1 (sr) *	2015-08-05	2022-03-31	Eisai R&D Man Co Ltd	Postupak za pripremu suštinski dijastereomerno čistog fosforodiamidatnog oligomera, fosforodiamidatni oligomer proizveden takvim postupkom i farmaceutska kompozicija koja sadrži fosforodiamidatni oligomer

2016
- 2016-08-05 RS RS20220178A patent/RS62930B1/sr unknown
- 2016-08-05 MA MA44209A patent/MA44209B1/fr unknown
- 2016-08-05 ES ES16767053T patent/ES2907629T3/es active Active
- 2016-08-05 UA UAA201802109A patent/UA123995C2/uk unknown
- 2016-08-05 WO PCT/US2016/045876 patent/WO2017024264A2/fr not_active Ceased
- 2016-08-05 NZ NZ778825A patent/NZ778825A/en unknown
- 2016-08-05 MD MDE20180593T patent/MD3331891T2/ro unknown
- 2016-08-05 SM SM20220089T patent/SMT202200089T1/it unknown
- 2016-08-05 HU HUE16767053A patent/HUE057593T2/hu unknown
- 2016-08-05 SI SI201631470T patent/SI3331891T1/sl unknown
- 2016-08-05 EP EP16767053.8A patent/EP3331891B1/fr active Active
- 2016-08-05 CA CA3296518A patent/CA3296518A1/fr active Pending
- 2016-08-05 IL IL293066A patent/IL293066A/en unknown
- 2016-08-05 PL PL16767053T patent/PL3331891T3/pl unknown
- 2016-08-05 MX MX2018001557A patent/MX389022B/es unknown
- 2016-08-05 PE PE2023000140A patent/PE20231843A1/es unknown
- 2016-08-05 IL IL284611A patent/IL284611B2/en unknown
- 2016-08-05 NZ NZ778828A patent/NZ778828A/en unknown
- 2016-08-05 PE PE2018000192A patent/PE20180687A1/es unknown
- 2016-08-05 LT LTEPPCT/US2016/045876T patent/LT3331891T/lt unknown
- 2016-08-05 AU AU2016302009A patent/AU2016302009B2/en active Active
- 2016-08-05 US US15/750,087 patent/US10457698B2/en active Active
- 2016-08-05 HU HUE21210674A patent/HUE067910T2/hu unknown
- 2016-08-05 KR KR1020247042650A patent/KR20250005537A/ko active Pending
- 2016-08-05 ES ES21210674T patent/ES2993126T3/es active Active
- 2016-08-05 PT PT167670538T patent/PT3331891T/pt unknown
- 2016-08-05 CN CN201680058501.2A patent/CN108350005B/zh active Active
- 2016-08-05 CN CN202410065464.4A patent/CN117924364A/zh active Pending
- 2016-08-05 KR KR1020187006255A patent/KR102788397B1/ko active Active
- 2016-08-05 DK DK16767053.8T patent/DK3331891T3/da active
- 2016-08-05 JP JP2018506149A patent/JP6978406B2/ja active Active
- 2016-08-05 EP EP21210674.4A patent/EP4039690B1/fr active Active
- 2016-08-05 CN CN202110735306.1A patent/CN113461733A/zh active Pending
- 2016-08-05 HR HRP20220129TT patent/HRP20220129T1/hr unknown
- 2016-08-25 MY MYPI2018000173A patent/MY196627A/en unknown
2018
- 2018-02-05 CL CL2018000322A patent/CL2018000322A1/es unknown
- 2018-02-05 IL IL257353A patent/IL257353B2/en unknown
- 2018-02-05 PH PH12018500265A patent/PH12018500265A1/en unknown
- 2018-02-06 MX MX2022000124A patent/MX2022000124A/es unknown
- 2018-02-19 CO CONC2018/0001615A patent/CO2018001615A2/es unknown
- 2018-03-05 ZA ZA2018/01518A patent/ZA201801518B/en unknown
2019
- 2019-08-15 ZA ZA2019/05394A patent/ZA201905394B/en unknown
- 2019-09-17 US US16/573,185 patent/US10836784B2/en active Active
2020
- 2020-10-28 US US17/082,070 patent/US20210171555A1/en not_active Abandoned
2021
- 2021-09-29 JP JP2021159804A patent/JP7254869B2/ja active Active
- 2021-12-21 AU AU2021290235A patent/AU2021290235B2/en active Active
2022
- 2022-01-21 ZA ZA2022/01010A patent/ZA202201010B/en unknown
- 2022-02-23 CY CY20221100159T patent/CY1125552T1/el unknown
2023
- 2023-03-29 JP JP2023053119A patent/JP7712975B2/ja active Active
- 2023-09-08 AU AU2023226763A patent/AU2023226763B2/en active Active
2024
- 2024-07-22 US US18/779,841 patent/US20250171475A1/en active Pending
2025
- 2025-03-03 JP JP2025032861A patent/JP2025090640A/ja active Pending

Also Published As

Publication number	Publication date
MX2018001557A (es)	2018-05-02
WO2017024264A3 (fr)	2017-03-30
MX2022000124A (es)	2022-02-16
CY1125552T1 (el)	2024-02-16
JP7254869B2 (ja)	2023-04-10
IL284611B2 (en)	2023-11-01
JP2022003067A (ja)	2022-01-11
PT3331891T (pt)	2022-02-28
PE20180687A1 (es)	2018-04-23
CO2018001615A2 (es)	2018-07-19
KR102788397B1 (ko)	2025-04-01
MX389022B (es)	2025-03-20
PE20231843A1 (es)	2023-11-21
US10457698B2 (en)	2019-10-29
PH12018500265A1 (en)	2018-08-13
US20210171555A1 (en)	2021-06-10
US10836784B2 (en)	2020-11-17
HUE067910T2 (hu)	2024-11-28
NZ740490A (en)	2024-07-05
ZA201801518B (en)	2020-10-28
IL257353B2 (en)	2023-02-01
AU2016302009A1 (en)	2018-03-29
IL257353B (en)	2022-10-01
IL293066A (en)	2022-07-01
ES2907629T3 (es)	2022-04-25
CN113461733A (zh)	2021-10-01
AU2021290235B2 (en)	2023-06-08
CN108350005B (zh)	2024-02-06
AU2023226763B2 (en)	2025-09-18
UA123995C2 (uk)	2021-07-07
US20200115405A1 (en)	2020-04-16
JP2025090640A (ja)	2025-06-17
BR122023025447A2 (pt)	2024-01-16
MY196627A (en)	2023-04-23
MD3331891T2 (ro)	2022-04-30
MA44209B1 (fr)	2022-03-31
ES2993126T3 (en)	2024-12-23
JP2023085402A (ja)	2023-06-20
KR20180044303A (ko)	2018-05-02
KR20250005537A (ko)	2025-01-09
ZA202201010B (en)	2024-05-30
EP3331891A2 (fr)	2018-06-13
EP3331891B1 (fr)	2021-12-15
HRP20220129T1 (hr)	2022-04-15
CA3296518A1 (fr)	2026-03-02
CN108350005A (zh)	2018-07-31
CA2994842A1 (fr)	2017-02-09
JP2018525380A (ja)	2018-09-06
NZ778828A (en)	2024-11-29
JP6978406B2 (ja)	2021-12-08
BR112018002430A2 (pt)	2018-09-18
LT3331891T (lt)	2022-02-25
CN117924364A (zh)	2024-04-26
PL3331891T3 (pl)	2022-03-28
AU2021290235A1 (en)	2022-01-20
EP4039690A1 (fr)	2022-08-10
ZA201905394B (en)	2022-07-27
HUE057593T2 (hu)	2022-05-28
IL284611B1 (en)	2023-07-01
RS62930B1 (sr)	2022-03-31
SMT202200089T1 (it)	2022-03-21
RU2018107663A (ru)	2019-09-05
JP7712975B2 (ja)	2025-07-24
HK1248708A1 (zh)	2018-10-19
CL2018000322A1 (es)	2018-05-18
WO2017024264A8 (fr)	2018-04-12
US20250171475A1 (en)	2025-05-29
AU2016302009B2 (en)	2021-09-30
RU2018107663A3 (fr)	2020-05-21
NZ778825A (en)	2024-11-29
AU2023226763A1 (en)	2023-09-28
EP4039690B1 (fr)	2024-07-17
WO2017024264A2 (fr)	2017-02-09
SI3331891T1 (sl)	2022-04-29
IL257353A (en)	2018-04-30
IL284611A (en)	2021-08-31
DK3331891T3 (da)	2022-02-28
EP4039690C0 (fr)	2024-07-17
US20180222932A1 (en)	2018-08-09

Publication	Publication Date	Title
EP3357491A4 (fr)	2019-05-08	Composition pharmaceutique contenant un médicament anionique, et son procédé de préparation
EP3351242A4 (fr)	2019-05-15	Composition pharmaceutique orale comprenant un cannabinoïde, procédé pour sa préparation et son utilisation
ZA201808286B (en)	2021-07-28	New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MY190561A (en)	2022-04-27	New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000521A1 (en)	2019-04-12	New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en)	2019-04-12	New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
EP3486242A4 (fr)	2019-12-04	Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
ZA201405101B (en)	2015-12-23	"new indolizine compounds, a process for their preparation and pharmaceutical compositions containing them."
TW201613859A (en)	2016-04-16	Analogs of PRIDOPIDINE, their preparation and use
MY196562A (en)	2023-04-19	New Piperidinyl Derivatives, a Process for Their Preparation and Pharmaceutical Compositions Containing Them
TN2017000529A1 (en)	2019-04-12	New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX348370B (es)	2017-06-08	Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
HUE057593T2 (hu)	2022-05-28	Eljárás lényegében diasztereomeresen tiszta foszfor-diamidát oligomer elõállítására, az eljárással készített foszfor-diamidát oligomer és a foszfor-diamidát oligomert tartalmazó gyógyszerészeti készítmény
EP3398615A4 (fr)	2019-09-25	Composition pharmaceutique mucoadhésive et son procédé de préparation
ZA201604976B (en)	2022-05-25	Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them
EP2742020A4 (fr)	2015-03-11	Dérivé de biguanide à substitution n1-amine cyclique-n5, procédés de préparation associés et composition pharmaceutique les comprenant
EA201691741A1 (ru)	2017-02-28	Фармацевтическая композиция
EP3708173A4 (fr)	2022-03-02	COMPOSITION PHARMACEUTIQUE THÉRAPEUTIQUE POUR LE CANCER COMPRENANT UN miARN
EP2941418A4 (fr)	2016-10-26	Dérivés de biguanide à substitution n1-amine cyclique-n5, leurs procédés de préparation et composition pharmaceutique les comprenant
EP3369725A4 (fr)	2019-05-01	Sel pharmaceutique dérivé de la polyamine, son procédé de préparation et son utilisation
IL282218A (en)	2021-05-31	New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EP3305283A4 (fr)	2019-01-09	Composition pharmaceutique stabilisée et son procédé de préparation
PL3589622T3 (pl)	2021-10-18	Sposób przygotowywania jodku 3,7-bis(dimetyloamino)fenotiazyn-5-yliowego
EP3328435A4 (fr)	2019-03-13	Composition pharmaceutique à stabilité au stockage améliorée, et son procédé de préparation
MX2020011170A (es)	2020-11-12	Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona.